RSPR Pharma is a Swedish pharmaceutical company developing an oral anti-asthmatic drug providing mast cell control by inhibiting both induced and basal release of asthma mediators.

Asthma is an inflammatory condition affecting some 300 million people worldwide and despite gold standard therapy (inhaled corticosteroids, which do not target mast cells) only 50% of patients reach asthma control. The RSPR Pharma compound is currently in clinical development and is intended for patients not controlled by corticosteroids.

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.